Atisama Therapeutics is VC-Backed and has raised funding across Series A and Seed rounds. It is backed by Monash Investment Holdings and The University of Western Australia.
Alternatives.pe tracks Atisama Therapeutics's funding history, valuation trends, ownership structure, and transaction activity over time.
Last Updated: 2026-07-21
Explore the latest updates and insights
Atisama Therapeutics (formerly RAGE Biotech), has been awarded more than AUD 15 million through the Australian Government's Medical Research Future Fund (MRFF).
Monash spinout RAGE Biotech secures $29 million to advance next-generation RNA therapeutics. The ... see summary
IP Group leads $3.7 million seed round into RAGE Biotech
A view of the number of employees over time
Key members of the management team